Loading the session
Loading the session
Loading instrument
$30.35
−1.91%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:37 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $30.94 on 4 Nov 2026: 1.7% below the 52-week high of $31.49 (4 Nov 2026) and 93.3% above the low of $16.00 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
1 month: +20.6% (SPY −1.6%). 3 months: +31.7% (SPY −0.4%). 1 year: +70.4% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ZYME, SPY · as of 4 Nov 2026
3 Nov 2026 volume of 2.5M shares was 2.0× the average of the 30 sessions before it (1.3M), as the price rose 3.9%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
The 4 Nov 2026 close of $30.94 was 12.9% above its 50-day average ($27.40) and 22.2% above its 200-day average ($25.32). It has closed above the 200-day for 13 sessions, since 19 Oct 2026. The 50-day average crossed above the 200-day on 26 Aug 2026, 49 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 14-session relative strength index closed at 71.2 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
November 17, 2025
+29.05%December 21, 2022
+23.59%September 6, 2022
−28.85%